acute myeloid leukemia myelodysplastic syndromes
TRANSCRIPT
![Page 1: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/1.jpg)
Acute myeloid
leukemia
Myelodysplastic
syndromes
![Page 2: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/2.jpg)
Acute leukemia in adults
70% myeloid, 30% lymphoid
Average age at presentation is 60 years.
60% of the patients is older than 55-60 years.
Clinical presentation: deficiency of functional blood cells( anaemia, thrombocytopenia, neutropenia) or infiltration of the organs by immature leukemic blasts
>20% blasts on the bone marrow (BM is usually hypercellular, rarely hypoplastic).
Flow cytometry/ citochemistry is required for further classification (ALL/AML)- therapy is different!!!
Survival is just weeks or months without treatment
![Page 3: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/3.jpg)
Clinical presentation ♦ Pancytopenia:
fever, infection, anaemia, bleeding
♦ Signs og malignant proliferation:
pain in the bones, lymphadenomegaly, meningeal signs
♦ Compression signs
(MYELOID SARCOMA!)
![Page 4: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/4.jpg)
AML
M0
M2
M1
M4-M5b
M5a
FAB subtype NameAdult AML patients
(%)
M0Undifferentiated acute
myeloblastic leukemia5%
M1
Acute myeloblastic
leukemia with minimal
maturation
15%
M2
Acute myeloblastic
leukemia with
maturation
25%
M3Acute promyelocytic
leukemia10%
M4Acute myelomonocytic
leukemia20%
M4eos
Acute myelomonocytic
leukemia with
eosinophilia
5%
M5Acute monocytic
leukemia10%
M6Acute erythroid
leukemia5%
M7Acute megakaryocytic
leukemia5%
![Page 5: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/5.jpg)
AML WHO classification
AML with recurrent genetic abnormalities:
• t(8;21), inv(16) or t(16;16), t(15;17), t(9;11), t(6;9), inv(3)or t(3;3), t(1;22)
AML with myelodysplasia-related change
Therapy-related myeloid neoplasms
AML, not otherwise specified: M0-M7
Myeloid sarcoma
Myeloid proliferations related to Down syndrome:
• Transient abnormal myelopoiesis
• Myeloid leukemia associated with Down syndrome (50x incidence !!!)
![Page 6: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/6.jpg)
![Page 7: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/7.jpg)
Therapy
High dose therapy with the aim of cure
Palliative- to decrease malignant cell burden
Best supportive care
![Page 8: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/8.jpg)
Favorable
t(8;21) (q22;q22); RUNX1-RUNX1T1
inv(16) (p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Mutated NPM1 without FLT3-ITD (normal karyotype)
Mutated CEBPA (normal karyotype)
Intermediate-I
Mutated NPM1 and FLT3-ITD (normal karyotype)
Wild type NPM1 and FLT3-ITD (normal karyotype)
Wild type NPM1 without FLT3-ITD (normal karyotype)
Intermediate-II t(9;11)(p22;q23); MLLT3-MLL
Adverse
inv(3) (q21q26.2) or t(3;3) (q21;q26.2); RPN1-EVI1
t(6;9) (p23;q34); DEK-NUP214
t(v;11) (v;q23); MLL rearranged
-5 or del(5q);
-7;
del17p;
complex karyotype; monosomal karyotype
![Page 9: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/9.jpg)
High dose therapy in non-M3 AML
Induction: aim is complete remission (CR):
<5% blasts in BM, no blast and normal cell
count in PB (10E8 leukemic cells left!)
„7+3” protocol: AraC+anthracyclin
Postremission treatment: aim is elimination of
residual cells (chemotherapy like high-dose
AraC or alloPBSCT)
![Page 10: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/10.jpg)
Graft sources
![Page 11: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/11.jpg)
HLA class II HLA class I
antigens
DP DQ DR B C A
6 9 19 46 10 21
MHC (224 genes)
6
Human Major Histocompatibility Complex
B1 A1 B1 A1 B3
B4
B5
A1B1
alleles(DNA) 126 81 559 851 276 506
(2400)
![Page 12: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/12.jpg)
HLA genotypically
identical sib
DP ACwDQ DR B
related
A/B/C
DR/DQ/DP
A/B/C
DR/DQ
12/12
10/10
A/B/DR 6/6
unrelated
A/B/C/DR 8/8
![Page 13: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/13.jpg)
HLA matching
Donor age
CMV (-) for CMV(-) patients
Gender (male)
Pregnancy
ABO
Body mass
![Page 14: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/14.jpg)
Much of the benefit of alloSCT is
due to immune GVL effect
![Page 15: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/15.jpg)
Transplant related mortality
Early effects: – Infection, sepsis
– Mucositis (etoposid, MTX)
– Haemorrhagic cystitis (cyclophosphamid, adenovirus, BK virus)
– GVHD
– Graft failure
– Transplant related lung injury, interstitial pneumonitis (CMV)
– Venoocclusive disease (damage of sinosoidal endothelium-jaundice,
fluid retention)
– Transplantation associated thrombotic microangiopathy
![Page 16: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/16.jpg)
Graft Versus Host Disease
Acute (<100 days)
skin-mucosa
gut
liver
Chronic
skin, eye, mouth, lung, liver, etc. oral ulcerations (lichen planus), keratoconjunctivitis sicca, xerostomia, polyserositis, esophagitis and stricture, intrahepatic obstructive liver disease, obstructive pulmonary disease, scleroderma, morphea,
fasciitis and myositis
![Page 17: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/17.jpg)
Acut Promyelocytic Leukemia
FAB M3
Distinct entity: t(15;17) PML-RARa
RARa keeps DNA and ligand binding properties:
Co-repressors dissociate with farmacologic
doses of retinoids
![Page 18: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/18.jpg)
APL
Clinical:
• BM infiltration with promyelocytes
• first signs are DIC/hyperfibrinolysis
Therapy:
„urgency leukemia”
All-trans retinoic acid (ATRA) in case of APL suspicion
![Page 19: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/19.jpg)
APL therapyInduction + consolidation + maintenance
Protocol:
AIDA (ATRA+Idarubicin)+ risk-adapted consolidation therapy
ATRA+ATO (arsenic trioxide)
(first chemo free regimen!!)
Results: 90-95% Complete remission
CAVE: differentiation sy (fever, hypertension, oedema, pulmonal
infiltrate, pseudotumor cerebri)
![Page 20: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/20.jpg)
Lo-Coco F et al. N Engl J Med 2013;369:111-121.
![Page 21: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/21.jpg)
Elimination of leukemic blasts and LICs is necessary for definitive cure of APL. LICs posses high self-renewal capability and give rise to leukemic blasts that form the bulk of the disease
dos Santos G A et al. J Exp Med 2013;210:2793-2802
© 2013 dos Santos et al.
![Page 22: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/22.jpg)
Treatment in patients over 60
Comorbidities: OH-Urea, haemosupportation
Low intensity chemotherapy:
hypomethylating agents: AzaC, Decitabin
sc low dose AraC
7+3: 100-200 mg/m2 AraC + 45-60 mg/m2 daunorubicin
clofarabine (monoth?, +AraC?,
+hypomethylating agent)
![Page 23: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/23.jpg)
Myelodysplasia
Clonal disease of haematopoietic stem cells: insufficient
haemopoiesis and dysplasia in one or more cell lines
Clinical:
-ineffective haematopoiesis (increased apoptosis)- cytopenia
and progressive BM insufficiency
-leukemic transformation is possible
![Page 24: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/24.jpg)
Epidemiology:
Average age around 70 years
3/100000/year
Can be due to previous radio- or chemotherapy
30% leukemic transformation
Diagnosis:
♦Peripheral blood count
♦BM biopsy and aspiration
♦Cytogenetic evaluation
Other CAUSES HAVE TO BE EXCLUDED:
♦Vitamin (B12,folic acid) deficiency
♦Chr. Liver diseases
♦Malignant diseases
♦HIV
♦Autoimmune diseases
♦Ring sideroblasts: alcoholism, As or Pb exposition,
drugs, congenital haematopoietic diseases
![Page 25: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/25.jpg)
Etiology
Familiar: rare
Therapy related (t-MDS)
CAUSE IS USUALLY UNKNOWN
![Page 26: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/26.jpg)
Peripheral blood
Heterogenous disease
Sine qua non: Quantitative deficiency in one or more cell lines
Anaemia:
– Isolated cytopenia without anaemia is rare(<5%)
Leukopenia: ~50%
Trombocytopenia: ~25%
Pancytopenia: 50% at diagnosis
![Page 27: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/27.jpg)
Morphology in PB:
RBC: anisocytosis
macro-ovalocytosis
basophilic punctation
Granulocyte:
deficient granulation
hypo- or hyperlobulated nuclei
Thrombocytopenia (except 5q-)
Blasts
![Page 28: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/28.jpg)
RBC
Anaemia
Retikulocyte count is low
Normocytic or macrocytic
Elliptocytes, dacrocytes
2 different RBC poplutation could be observed
Nucleated RBCs
![Page 29: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/29.jpg)
MDS:
WBC Granulocytopenia:
~50% at dg
Nuclei:– Decreased
segmentation(“pseudo-Pelger-Huët” anomaly)
– Ring form
Cytoplasm: decreased or absent granulation
![Page 30: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/30.jpg)
Platelets
Thrombocytopenia: ~25% at diagnosis
– Isolated thrombocytopenia rare as first
presentation sign
Giant thrombocytes
5q- sy: thrombocytosis could be seen.
![Page 31: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/31.jpg)
WHO classification
Refractory anaemia (RA): cytopenia in one or two cell lines,
blasts <5%, ring sideroblasts<15%
RA with ring sideroblast (RARS): ring sideroblasts >15%
Refractory cytopenia with dysplasia in two or more cell lines (RCMD):
>10% dysplastic cells, <5% blasts,
RAEB-1: 5-9% blasts
RAEB-2: 10-19% blasts
MDS/MPDS
Del(5q): Anaemia, blasts <5%, normal or elevated platelet count
(female predominance, transformation is rare)
>20% blasts =ACUTE LEUKEMIA
![Page 32: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/32.jpg)
WHO classification-based prognostic
scoring system for myelodysplasias
Karyotypes: Good = normal, -Y, del(5q-) only, del(20q-) only. Poor = complex (≥3
abnormalities), or chromosome 7 abnormalities. Intermediate = all others.
Transfusion dependency is defined as at least one red transfusion every 8 weeks
over a period of 4 months.
![Page 33: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/33.jpg)
IPSS-R calculator: http://www.ipss-r.com
![Page 34: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/34.jpg)
![Page 35: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/35.jpg)
Pathogenesis of ring
sideroblasts
Cazzola M et al. Blood. 121(2):260-9
![Page 36: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/36.jpg)
Treatment
♦ Supportive care: RBC and THR transfusion
Iron chelators: decreased organ damage and improved
hematological response
♦ Biologic response modifiers:
♦ Immune modulating agents (lenalidomide)
♦ Growth factors (Epo, G-CSF) TPO receptor antagonists???
♦ Immunosuppressive agents (cyclosporine, ATG)
♦ Hypomethylating agents (decitabin, azacitidin)
♦ High-dose chemotherapy
♦ AlloPBSCT
![Page 37: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/37.jpg)
Therapeutic choices
Del5q: lenalidomide
Transfusion dependent, seEpo<500 U/l: Epo +/- G-CSF
Hypoplastic variant: ATG (anti-thymocyte globulin)/cyclosporin
Thr-penia/neutropenia, high risk: demethylating agents- Azacitidine, decitabin
High risk, suitable for high dose chemotherapy: chemotherapy -
alloPBSCT
![Page 38: Acute myeloid leukemia Myelodysplastic syndromes](https://reader031.vdocuments.mx/reader031/viewer/2022012412/616bd7db86b5bf7f20789fad/html5/thumbnails/38.jpg)
Lenalidomide in del5q MDS